Skip to main content Skip to secondary navigation

Browse Stanford's available technologies by keyword or collection today by exploring our Techfinder Catalog.

Mitochondrial transplantation therapy for heart failure

Main content start

Image Credit: ART-ur / Shutterstock.com

Extracellular vesicles delivering functional mitochondria directly to damaged cardiomyocytes.

About the Technology

Heart failure remains a leading cause of morbidity and mortality worldwide, with limited options for patients in advanced stages.

Our innovative therapy utilizes extracellular vesicles from universal donor cells, engineered to deliver functional mitochondria directly to damaged cardiomyocytes, addressing the underlying cellular dysfunction rather than just symptoms. We have demonstrated efficacy in a preclinical pig model of chronic heart failure utilizing a catheter-mediated minimally invasive approach.

During the HIT Fund program, we aim to optimize dosage, conduct FDA-compliant safety trials, and investigate the durability of therapeutic effects, paving the way for regulatory submissions and clinical applications.

Team Members

Phillip C. Yang

Phillip C. Yang

Professor of Medicine (Cardiovascular Medicine)

View Stanford Profile

Yasuhiro Shudo

Yasuhiro Shudo

Clinical Assistant Professor, Cardiothoracic Surgery - Adult Cardiac Surgery

View Stanford Profile

Gentaro Ikeda

Gentaro Ikeda

Instructor, Medicine - Med/Cardiovascular Medicine

View Stanford Profile

Priyanka Seegobin

Priyanka Seegobin

MBA Intern

View Stanford Profile

Related Web Links